1643P Impact of PTEN alterations on clinical outcomes in patients (pts) with de novo metastatic prostate cancer (mPC)

B. Thapa; N. Henderson; S.T. Tagawa; C. Hwang; A.O. Sokolova; M.A. Bilen; P.M. Coelho Barata; C.B. Nguyen; A. Tripathi; A. Ayanambakkam; L.S. Graham; Y. Zakharia; V.S. Koshkin; E. Heath; T.B. Dorff; A.J. Armstrong; R.R. McKay; A.S. Alva; M. Schweizer; D. Kilari

doi:10.1016/j.annonc.2024.08.1724

Back

1643P Impact of PTEN alterations on clinical outcomes in patients (pts) with de novo metastatic prostate cancer (mPC)

Abstract

Peer reviewed

1643P Impact of PTEN alterations on clinical outcomes in patients (pts) with de novo metastatic prostate cancer (mPC)

B. Thapa, N. Henderson, S.T. Tagawa, C. Hwang, A.O. Sokolova, M.A. Bilen, P.M. Coelho Barata, C.B. Nguyen, A. Tripathi, A. Ayanambakkam, …

Annals of oncology, Vol.35(Supplement 2), pp.S991-S991

09/2024

DOI: 10.1016/j.annonc.2024.08.1724

View Online

Abstract

Background Compound alterations in TP53, RB1, and/or PTEN have been correlated with poor outcomes in pts with mPC; however, there is limited data regarding whether PTEN alterations(alt) by next generation sequencing (NGS) are prognostic in isolation. PTEN -null de novo mPC is currently being investigated in CAPItello-281 and may represent a clinically actionable subtype. As such, we sought to characterize outcomes of this genomically defined subgroup. Methods PROMISE is a multi-institutional database including mPC pts (N=2027) with NGS. Using PROMISE, we analyzed outcomes based on PTEN status in de novo mPC pts. Results Among 1036 pts with de novo mPC, 212 (20%) had PTEN alt by NGS. Median age at diagnosis was 64 yrs, 21% were Black, 53% had high volume (HV) disease. Compared to the PTEN-wildtype (wt) group, PTEN-altered mPC had higher co-occurrence of TP53 and/or RB1 mutations (57% vs 37%); lower median PSA (38 vs 63 ng/ml); and more visceral disease (18 vs 11%). Groups were otherwise similar. The table shows univariate (UVA) outcomes based on PTEN status. Outcomes were similar in men with high volume disease on UVA. On multivariable analysis controlling for clinical prognostic features and TP53/RB1 alterations, PTEN status remained independently associated with overall survival (OS) [HR 1.27, 95% CI (0.99, 1.63) p=0.05]. Conclusions PTEN status correlated with poor outcomes in de novo mPC independent of other clinical and genomic factors.

Details

Title: Subtitle: 1643P Impact of PTEN alterations on clinical outcomes in patients (pts) with de novo metastatic prostate cancer (mPC)
Creators: B. Thapa - Medical College of Wisconsin
N. Henderson - U-M Rogel Cancer Center
S.T. Tagawa - Weill Cornell Medicine
C. Hwang - Henry Ford Health System
A.O. Sokolova - Oregon Health & Science University
M.A. Bilen - Winship Cancer Institute
P.M. Coelho Barata - University Hospitals Seidman Cancer Center
C.B. Nguyen - University of Michigan
A. Tripathi - City Of Hope National Medical Center
A. Ayanambakkam - OU Health
L.S. Graham - University of Colorado Cancer Center
Y. Zakharia - University of Iowa
V.S. Koshkin - University of California San Francisco Medical Center
E. Heath - The Barbara Ann Karmanos Cancer Institute
T.B. Dorff - City Of Hope National Medical Center
A.J. Armstrong - Duke Cancer Institute
R.R. McKay - University of California San Diego
A.S. Alva - University of Michigan
M. Schweizer - University of Washington
D. Kilari - Medical College of Wisconsin
Resource Type: Abstract
Publication Details: Annals of oncology, Vol.35(Supplement 2), pp.S991-S991
DOI: 10.1016/j.annonc.2024.08.1724
ISSN: 0923-7534
Publisher: Elsevier Ltd
Language: English
Date published: 09/2024
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
Record Identifier: 9984708762502771

Metrics

41 Record Views